loading

Protagonist Therapeutics Inc (PTGX) 最新ニュース

pulisher
07:42 AM

Wedbush Expects Higher Earnings for Protagonist Therapeutics - MarketBeat

07:42 AM
pulisher
04:19 AM

Quest Partners LLC Increases Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

04:19 AM
pulisher
Nov 20, 2024

Protagonist takes center stage with Phase III fillip - The Pharma Letter

Nov 20, 2024
pulisher
Nov 20, 2024

Protagonist Therapeutics' chief medical officer sells $78,107 in stock By Investing.com - Investing.com Australia

Nov 20, 2024
pulisher
Nov 20, 2024

Protagonist Therapeutics' chief medical officer sells $78,107 in stock - Investing.com India

Nov 20, 2024
pulisher
Nov 19, 2024

New oral psoriasis mechanism from Protagonist-J&J yields competitive Phase III data - BioCentury

Nov 19, 2024
pulisher
Nov 19, 2024

Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap DownHere's Why - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Protagonist, J&J’s oral IL-23 psoriasis data strong (but short) - BioWorld Online

Nov 19, 2024
pulisher
Nov 19, 2024

Protagonist Therapeutics (NASDAQ:PTGX) Given Outperform Rating at Wedbush - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Protagonist Therapeutics (NASDAQ:PTGX) Earns Buy Rating from HC Wainwright - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate - AccessWire

Nov 19, 2024
pulisher
Nov 19, 2024

Protagonist Therapeutics to Unveil New Oral IL-17 Drug Candidate, Share Key Study Data | PTGX Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 18, 2024

Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis - WSIL TV

Nov 18, 2024
pulisher
Nov 18, 2024

Protagonist Therapeutics Enters Oversold Territory (PTGX) - Nasdaq

Nov 18, 2024
pulisher
Nov 18, 2024

Protagonist's Psoriasis Drug Shows 74% Success Rate, Secures $165M Milestone Payment | PTGX Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 17, 2024

Janney Montgomery Scott LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Nov 17, 2024
pulisher
Nov 16, 2024

Amalgamated Bank Buys 15,301 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Nov 16, 2024
pulisher
Nov 16, 2024

Amalgamated Bank Acquires 15,301 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Nov 16, 2024
pulisher
Nov 15, 2024

What is HC Wainwright’s Forecast for PTGX FY2024 Earnings? - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

HC Wainwright Analysts Increase Earnings Estimates for PTGX - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

HC Wainwright Brokers Decrease Earnings Estimates for PTGX - Defense World

Nov 14, 2024
pulisher
Nov 13, 2024

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

HC Wainwright Issues Pessimistic Estimate for PTGX Earnings - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

US Bancorp DE Lowers Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Nov 13, 2024
pulisher
Nov 10, 2024

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 10, 2024
pulisher
Nov 10, 2024

New York State Teachers Retirement System Invests $1.11 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Nov 10, 2024
pulisher
Nov 10, 2024

New York State Teachers Retirement System Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Nov 10, 2024
pulisher
Nov 10, 2024

Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High – Should You Buy? - Defense World

Nov 10, 2024
pulisher
Nov 09, 2024

Creative Planning Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

What is Wedbush’s Forecast for PTGX Q3 Earnings? - Defense World

Nov 08, 2024
pulisher
Nov 08, 2024

Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week HighWhat's Next? - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Protagonist Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com UK

Nov 08, 2024
pulisher
Nov 07, 2024

What is Wedbush's Estimate for PTGX Q3 Earnings? - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Protagonist Therapeutics Inc (PTGX) Q3 2024 Earnings: EPS Loss o - GuruFocus.com

Nov 07, 2024
pulisher
Nov 07, 2024

Protagonist Therapeutics: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 07, 2024
pulisher
Nov 07, 2024

Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Joplin Globe

Nov 07, 2024
pulisher
Nov 07, 2024

Protagonist (PTGX) Reports $583M Cash Position, Key Trial Results Due Q4 2024 | PTGX Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

Financial Enhancement Group LLC Purchases Shares of 41,818 Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Wedbush Initiates Coverage of Protagonist Therapeutics (PTGX) with Outperform Recommendation - MSN

Nov 06, 2024
pulisher
Nov 06, 2024

Wedbush Reiterates “Outperform” Rating for Protagonist Therapeutics (NASDAQ:PTGX) - Defense World

Nov 06, 2024
pulisher
Nov 05, 2024

Protagonist Therapeutics (NASDAQ:PTGX) Shares Down 5.4%Here's What Happened - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting - Weatherford Democrat

Nov 05, 2024
pulisher
Nov 05, 2024

Protagonist's Rusfertide Phase 2 Trial Results Set for Major ASH Meeting Reveal | PTGX Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 05, 2024

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World

Nov 05, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Protagonist Therap - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $52.83 - Defense World

Nov 04, 2024
pulisher
Nov 03, 2024

State of Alaska Department of Revenue Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Nov 03, 2024
pulisher
Nov 02, 2024

Louisiana State Employees Retirement System Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Protagonist Therapeutics (NASDAQ:PTGX) shareholders are still up 353% over 5 years despite pulling back 3.0% in the past week - Simply Wall St

Nov 01, 2024
pulisher
Nov 01, 2024

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of "Buy" from Analysts - MarketBeat

Nov 01, 2024
pulisher
Oct 29, 2024

Allspring Global Investments Holdings LLC Increases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Oct 29, 2024
pulisher
Oct 29, 2024

Allspring Global Investments Holdings LLC Buys 103,414 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

Protagonist Therapeutics stock hits 52-week high at $48.34 By Investing.com - Investing.com South Africa

Oct 28, 2024
pulisher
Oct 28, 2024

Protagonist Therapeutics stock hits 52-week high at $48.34 - Investing.com India

Oct 28, 2024
pulisher
Oct 28, 2024

Cavalier Investments LLC Purchases New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Short Interest Update - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Cwm LLC Increases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Oct 28, 2024
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
大文字化:     |  ボリューム (24 時間):